Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Jaguar Health Inc.

    NASDAQ: JAGX · Real-Time Price · USD
    12.47
    0.23 (1.88%)
    At close: May 01, 2025, 3:59 PM
    12.10
    -2.97%
    After-hours: May 01, 2025, 05:43 PM EDT
    1.88%
    Bid 11.78
    Market Cap 8.4M
    Revenue (ttm) 11.69M
    Net Income (ttm) -38.49M
    EPS (ttm) -130.69
    PE Ratio (ttm) -0.1
    Forward PE -0.5
    Analyst n/a
    Ask 12.42
    Volume 102,277
    Avg. Volume (20D) 99,711
    Open 11.91
    Previous Close 12.24
    Day's Range 11.51 - 12.74
    52-Week Range 4.02 - 540.00
    Beta 1.11

    About JAGX

    Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer fo...

    [Read more]
    Industry Biotechnology
    Sector Healthcare
    IPO Date May 12, 2015
    Employees 49
    Stock Exchange NASDAQ
    Ticker Symbol JAGX
    Website https://jaguar.health
    Full Company Profile

    Next Earnings Release

    Jaguar Health Inc. is scheduled to release its earnings on May 13, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    -47.74%
    Jaguar Health shares are trading lower after the c... Unlock content with Pro Subscription
    8 months ago
    -10.83%
    Jaguar Health shares are trading lower after the company reported worse-than-expected second-quarter results.
    news image

    2 days ago · accessnewswire.com

    Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients

    Jaguar to host investor webcast today at 8:30 AM Eastern to review the initial results from the proof-of-concept study of crofelemer for MVID and SBS-IF presented April 26 at the Annual ELITE PED-GI C...

    news image

    3 days ago · accessnewswire.com

    REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)

    The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for c...

    news image

    2 weeks ago · accessnewswire.com

    Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress

    Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and mi...

    news image

    2 weeks ago · accessnewswire.com

    Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting

    The statistically significant responder analysis results for Mytesi® (crofelemer) in the Phase 3 OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 20...

    news image

    3 weeks ago · accessnewswire.com

    Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product

    Gelclair ® is the company's third commercialized prescription product Oral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most signifi...

    news image

    4 weeks ago · accessnewswire.com

    Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 4, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective April 3, 2025, the Company granted 3,600 res...

    news image

    1 month ago · accessnewswire.com

    Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules

    SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 1, 2025 / Jaguar Health, Inc. ( NASDAQ:JAGX ) ("Jaguar" or "the Company"), today announced the closing of its previously announced private placement...

    news image

    1 month ago · seekingalpha.com

    Jaguar Health, Inc. (JAGX) Q4 2024 Earnings Call Transcript

    Jaguar Health, Inc. (NASDAQ:JAGX ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Conference Call Participants Operator Greetings, and welcome to the Jaguar Health Inv...

    news image

    1 month ago · accessnewswire.com

    Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023

    The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus ...

    news image

    1 month ago · accessnewswire.com

    83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey

    Canalevia®-CA1 (crofelemer delayed-release tablets) is the first and only treatment for CID in dogs to receive any type of approval from the FDA In dogs undergoing chemotherapy, as is the case with pe...

    Create Price Alert on JAGX

    Your price alert will notify you when the stock price is above 12.47.

    Add to Watchlist